Background Several cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fi brosis in chronic hepatitis C. We examined the changes of TGF-β1 serum levels and their predictive value in patients with chronic hepatitis C under antiviral therapy.
Introduction
Chronic hepatitis C virus (HCV) infection is one of the most common causes of cirrhosis comprising 40% of chronic liver disease and representing a major health problem worldwide [1] . Chronic HCV infection is also associated with increased risk for development of hepatocellular carcinoma (HCC) [2] . However, many patients with chronic hepatitis C do not exhibit progressive disease or progress so slowly that cirrhosis does not develop within their lifespan. Th us, the factors determining increasing fi brosis and progressive disease remain largely unknown [3, 4] . For patients with clinically signifi cant hepatic fi brosis there is widespread agreement that antiviral therapy is indicated because of the high risk of cirrhosis [5] . Th erefore, it would be desirable to have specifi c predictive markers to distinguish patients potentially developing progressive liver disease from those with mild or stable disease.
Currently, therapeutic armamentarium for chronic HCV infection is rapidly changing since the classic therapeutic combination of pegylated interferon-α (Peg-IFNa) plus ribavirin gives places to specifi c antiviral drugs that achieve high sustained virological response (SVR) rates with excellent tolerance and safety [6] . However, the extremely high cost of the new therapies limits their widespread use in several parts of the world restricting them to patients with advanced fi brosis or cirrhosis or other specifi c subgroups [6] . Th erefore, many patients with chronic hepatitis C may be still treated with the previous treatment combination. In any case, the possible eff ects of antiviral treatment on the liver are expected to depend mostly on the virological response and HCV eradication but not on the type of therapy.
Recently, the scientifi c research has focused on several cytokines which may be associated with the persistence of HCV infection and the development of fi brosis. Such a cytokine is transforming growth factor (TGF)-β1, a 25-kDa homodimeric protein encoded by closely related genes; its physiological role lies in the regulation of cell growth and diff erentiation and depends on the target cells either as a positive stimulator or inhibitor of cell growth. In mammals, three isoforms have been thus far identifi ed; TGF-β1, 2 and 3 [7, 8] . In the liver, TGF-β1 has been involved in hepatic fi brogenesis, regulation of liver cell growth, tumor development and induction of hepatocellular apoptosis [9, 10] . TGF-β1 is produced by non-parenchymal liver cells, enhances the activity of hepatic stellate cells (HSCs) and inhibits the growth and proliferation of hepatocytes. In that way, TGF-β1 stimulates extracellular matrix and fi brous production [11, 12] . Increased levels of TGF-β1 mRNA have been identifi ed in patients with chronic liver disease with a positive correlation with levels of aminoterminal peptide of type III procollagen, a serum marker of hepatic fi brogenesis [13] . Some studies pointed out that serum levels of TGF-β1 are also increased in patients with chronic hepatitis C and are correlated with the degree of liver fi brosis while other investigators provide contradictory results [14] . Currently, there are some but not conclusive data on the changes of TGF-β1 levels aft er treatment with Peg-IFNa and ribavirin. Th erefore, the aim of current study was to examine the changes of TGF-β1 serum levels in patients with chronic hepatitis C under antiviral therapy.
Patients and methods
Our study group consisted of 84 patients with confi rmed chronic HCV infection evaluated at our outpatient liver clinics over a period of 12 months. Inclusion criteria were: 1) confi rmed chronic HCV infection (positive anti-HCV antibodies for at least 6 months and detectable serum HCV-RNA); 2) no history of previous HCV treatment (naïve patients); and 3) completion of a course with Peg-IFNa and ribavirin. Patients were excluded if they: 1) were co-infected with human immunodefi ciency virus (HIV) or other hepatitis viruses (HBV, HDV); 2) had HCC or any other malignancy;
3) were active users of illicit drugs; and 4) were alcohol abusers.
Blood samples were collected at baseline, at the end of therapy (EOT) and 6 months aft er the EOT. A full blood count, biochemical evaluation including alanine aminotransferase (ALT), aspartate aminotransferase (AS T), total bilirubin (T.Bil), albumin, coagulation tests [prothrombin time (PT) and international normalized ratio (INR), activated partial thromboplastin time (APTT)] were performed in each patient on the same day using commercially available assays. Samples were stored at -70 o C and analysis of TGB-β1 in pg/ mL was performed retrospectively on the same day using an ELISA method according to the manufacturer's instructions (Invitrogen Corporation, Camarillo, CA). ΗCV-RNA was determined by quantitative polymerase chain reaction (PCR) and measured in international units (IU/mL) while HCV genotype was defi ned by INNOLIPA.
Hepatic fi brosis was assessed by transient elastography (TE) (Fibroscan® Echosens Paris) according to current guidelines [15, 16] . Liver stiff ness measurements by TE were expressed in kilopascals (kPa) and were evaluated in relation to interquartile range (IQR) and to the success rate of measurements. IQR less than 30% of mean liver stiff ness and success rate more than 60% in more than 10 validated measurements were indicative of a successful measurement [15] . Based on previous studies, cut-off values of <6 KPa were considered normal, 6-8 KPa were considered within the gray range, 8-12.5 KPa F3 fi brosis, and a cut-off of >12.5 KPa was considered as F4 fi brosis [17] .
All patients were treated with Peg-IFNa in combination with ribavirin. Patients infected with genotypes 1 and 4 were treated for 48 weeks, whereas patients infected with genotypes 2 and 3 were treated for 24 weeks. For patients who stopped prematurely treatment due to side eff ects or no response (NR), the EOT was considered as the last day of treatment. Th ese patients were re-evaluated 6 months later and blood samples were collected for analysis. We considered as sustained responders (SVR) those patients with undetectable HCV-RNA (<50 IU/mL) at the EOT and at six-month follow up, whereas as non-responders (NR) those patients with detectable HCV-RNA at the EOT; patients with HCV-RNA undetectable at the EOT but detectable at six-months of post-treatment follow up were considered as relapsers (RR) [18] .
Statistical analysis
Results were subjected to routine statistical analysis using SPSS v. 20 (SPSS Inc, an IBM Company, Chicago, IL). Quantitative variables were expressed as mean values [standard deviation (SD)] . Comparisons of quantitative variables between two groups were performed using t-test, while comparisons of quantitative variables among more than two groups were performed using one way analysis of variance (ANOVA). Comparisons of the changes over time of quantitative variables within the same group were performed using paired t-test. A P value less than 0.05 was considered to be statistically signifi cant.
Results
Th e mean age of patients was 46 (SD: 15) years and 52% of them were male. Baseline characteristics are presented in Table 1 . Th irty seven of the patients had comorbidities including hypertension (n=11, 30%), diabetes mellitus II (n=3, 8%) or other (n=9, 24%). Genotype 1 was detected in 24 (28.6%), genotype 2 in 7 (8.3%), genotype 3 in 35 (41.7%) and genotype 4 in 17 patients (20.2%), while genotype could not be determined in 1 patient (1.2%).
Route of transmission of HCV infection was unknown in 46 (55%) patients. Of the remaining 38, 26 patients (68%) were intravenous drug users, 10 (26%) had a history of blood transfusions and 2 (5%) had a tattoo performed with unsterilized tools.
Of the 84 patients, based on HCV-RNA measurements, 64 patients (76%) achieved SVR, 7 patients (8.5%) responded at the EOT but relapsed during post-therapy follow up (RR) and 13 patients (15.5%) had NR. Nineteen (79.2%) patients with genotype 1 responded at the EOT and 15 (62.5%) achieved SVR at a six-month follow up. All 7 patients (100%) with genotype 2 achieved SVR, 31 (88.6%) patients with genotype 3 responded at the EOT and 30 (85.7%) achieved SVR and 14 (82.4%) patients with genotype 4 responded at the EOT and 12 (70.6%) achieved SVR. It should be noted that 14 patients showed adverse reactions to treatment. Th e most common adverse events were cytopenias (neutropenia and/or anemia) in 6 (7%), rash in 3 (4%), thyroiditis in 3 (4%) and depression in 2 (2%). Twelve patients (14%) stopped therapy prematurely due to adverse events (4 with genotype 1, 4 with genotype 3 and 4 with genotype 4). Mean (SD) baseline HCV-RNA levels were 2.9x10 6 (8.6x10 6 ) IU/ mL, while liver stiff ness at baseline had a mean (SD) level of 8.27 (6.06) kPa (Table 1) .
Mean (SD) TFG-β1 levels were 16,980 (11,643) pg/mL at baseline, 12,041 (8,972) pg/mL at the EOT and 13,254 (6,607) pg/mL at 6 months of follow up. Compared to baseline levels, TGF-β1 decreased at the EOT [mean diff erence: -3,829 pg/mL, 95% confi dence interval (CI): -2,314 to -5,344; P<0.001 by paired t-test] and at 6 months of posttreatment follow up (mean diff erence -3327 pg/mL, 95% CI: -946 to -5,708; P=0.001 by paired t-test). In particular, mean (SD) TGF-β1 levels decreased signifi cantly at the EOT and six months of post-treatment follow up compared to baseline only in patients with SVR (17,166 vs. 12327 pg/mL, P<0.0001 and 17,166 vs. 13,555 pg/mL, P=0.007, respectively, by paired t-test) (Fig. 1) (Table 2 ). On the other hand, a numerical but not statistically signifi cant decrease was usually observed in mean TGF-β1 levels from baseline to the EOT or to 6 months of post-treatment follow up in patients with RR (11,487 vs. 12,241 pg/mL, P=0.814 and 11,487 vs. 9,648 pg/mL, P=0.344, respectively) or NR (19, Patients were stratifi ed using baseline cut-off stiff ness values of less than 7.5 kPa and greater or equal to 7.5 kPa; statistically signifi cant association with TGF-β1 values was not found (3, 277) between the two groups. A second stratifi cation with baseline cut-off stiff ness values less than 6.5, between 6.5 and 9.5 and greater than 9.5 was performed; again, we could not fi nd any statistically signifi cant association with TGF-β1 values among the three groups.
Discussion
In this study, we included patients with chronic hepatitis C of all genotypes who attended our liver clinics and we measured serum TGF-β1 levels before and aft er treatment with PegIFNa and ribavirin. We found that TGF-β1 levels decreased substantially at the EOT and this diff erence was more pronounced and statistically signifi cant only in patients who achieved SVR. Mean TGF-β1 values slightly increased in patients with SVR during the 6-month period of follow up compared to values at the EOT but they never reached the pre-treatment levels and the diff erence remained statistically signifi cant compared to baseline. Mean TGF-β1 values had numerical declines from baseline to EOT and 6 months aft er EOT in patients without SVR, but the changes did not reach statistical signifi cance. Given that the number of patients without SVR was smaller than the number of patients who achieved SVR, a type II error for this association cannot be excluded.
We did not estimate the tissue expression of TGF-β1, as we used non-invasive methods (TE) for the estimation of liver fi brosis. Given that TGF-β1 is a pleiomorphic cytokine acting mostly locally at the site of infl ammation [19] , its serum level is a crude estimation of liver immunopathogenesis of HCV infection and treatment induced changes. However, it has previously shown that plasma levels of TGF-β1 are signifi cantly correlated with TGF-β1 content in liver tissue indicating that plasma levels may correspond reliably to tissue expression [20] .
Our results are similar but not identical to those of other studies that investigated the potential changes in serum levels and/or tissue expression of TGF-β1 aft er interferon treatment. Flisiak et al [21] also showed that TGF-β1 levels aft er treatment with Peg-IFNa and ribavirin decreased signifi cantly compared to baseline in a small number of patients, regardless of SVR, reaching levels observed in healthy volunteers. However, TGF-β1 levels increased signifi cantly 24 weeks aft er treatment in NRs compared to patients who achieved SVR. In initial studies in the '90s using IFNa monotherapy, increased expression of TGF-β1 mRNA in liver tissue was observed with normalization aft er 48 weeks of IFNa administration, suggesting an important role of this cytokine in the pathogenesis of chronic hepatitis C [22, 23] . Subsequent studies that estimated plasma TGF-β1 levels in patients with chronic hepatitis C who received conventional IFNa and ribavirin presented confl icting results. In one study [24] including 34 responders and 26 NRs to IFNa and ribavirin, serum TGF-β1 levels were found to decrease signifi cantly aft er treatment only in the responders, while mRNA TGF-β1 expression in liver tissue decreased signifi cantly in all patients independent of the achievement of SVR. On the other hand, while Janczewska et al reported that serum TGF-β1 levels decreased aft er treatment with IFNa and ribavirin in both responders and NRs [25] . Th ese diff erences might refl ect diff erent populations, diff erent stage of the disease or in the methodology of cytokine assessment. However, in agreement with our results, most studies have shown that IFNa administration reduces TGF-β1 plasma levels and/or TGF-β1 mRNA tissue expression in patients who achieve SVR.
Experimental studies have showed that bio-active TGF-β1 induces HSCs activation and invasion which likely contributes to liver fi brosis associated with HCV infection [26] . In our study, no association was found between TGF-β1 levels and liver fi brosis as estimated by TE at baseline or aft er therapy regardless of SVR. In accordance with our results, Roulot et al [27] reported that there was no association between TGF-β1 mRNA and either the biological and histological markers of liver fi brosis or a favorable response to IFNa therapy. Other studies have shown a correlation between plasma TGF-β1 levels and severity of liver fi brosis [28, 29] or close relationship between tissue TGF-β1 mRNA expression and serum markers of liver fi brosis, suggesting an active role in the fi brotic process [30, 31] . Moreover, in a recent small study including only genotype 4 patients, Gomaa et al [32] , showed that overexpression of TGF-β1 was an independent predictor of poor outcome to IFNa based therapy. In contrary, we did not fi nd any association between pre-treatment levels of TGF-β1 and response to therapy.
Th e diversity in the results of these trials is not easy to interpret. It is well recognized that advanced fi brosis is a negative predictive factor of response to IFNa treatment [18] . Profi brotic cytokines have been implicated in the impairment of IFNa signaling resulting in reduced effi cacy [33] . On the other hand, there is a complex interaction between viral proteins, TGF-β1 and IFNa signaling. Recent experimental studies provide further evidence to support the hypothesis that HCV enhances hepatic derangement progression through the generation of reactive oxygen Figure 1 Serum levels of transforming growth factor (TGF)-β1 (pg/mL) before (at baseline), at the end of therapy, and at 6 months aft er the end of pegylated interferon-α and ribavirin therapy in patients with chronic hepatitis C in relation to their sustained virological response (SVR). Compared to baseline, TGF-β1 levels were signifi cantly lower at end and 6 months aft er end of therapy in sustained responders (P<0.001 and P=0.001), but the change did not reach statistical signifi cance in non-sustained responders (P=0.227 and P=0.695) species and induction of TGF-β1 [34] [35] [36] . However, polymorphisms of the cytokines genes may aff ect the production and/or the action of TGF-β1 and despite the upregulation provoked by HCV proteins, the fi nal eff ect on the IFNa signaling is unpredictable [37, 38] . Th erefore, and in agreement with our results, it is not the absolute levels of TGF-β1 before treatment but possibly the changes following the administration of IFNa that refl ect the ability of therapy to overcome the negative eff ect of TGF-β1. A limitation of our study was that we did not measure the TGF-β1 levels in diff erent periods during treatment to possibly defi ne the earliest time point that TGF-β1 levels decline as a result of IFNa-based therapy. Such a study in the future could provide valuable information in support of the prognostic role of TGF-β1 levels during HCV treatment.
In conclusion, our results suggest that TGF-β1 serum levels decrease signifi cantly at EOT and 6 months of follow up, particularly in patients achieving SVR aft er Peg-IFNa and ribavirin. Th e long-term changes of TGF-β1 serum levels aft er HCV therapy need to be further investigated.
Summary Box
What is already known:
• Chronic hepatitis C can be a progressive disease leading to accumulation of liver fi brosis and perhaps to the development of cirrhosis • Antiviral therapy may achieve inhibition of the progression and even improvement in liver fi brosis in chronic hepatitis C patients • Several cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fi brosis in chronic hepatitis C
What the new fi ndings are:
• Serum TGF-β1 levels decrease signifi cantly aft er pegylated interferon-alfa and ribavirin therapy in chronic hepatitis C patients • Serum TGF-β1 levels decrease mostly in chronic hepatitis C patients who achieve sustained virological response • Serum TGF-β1 levels in chronic hepatitis C are not signifi cantly associated with liver stiff ness estimated by transient elastography
